PT2602260T - Process for preparing compound having hiv integrase inhibitory activity - Google Patents
Process for preparing compound having hiv integrase inhibitory activityInfo
- Publication number
- PT2602260T PT2602260T PT118146901T PT11814690T PT2602260T PT 2602260 T PT2602260 T PT 2602260T PT 118146901 T PT118146901 T PT 118146901T PT 11814690 T PT11814690 T PT 11814690T PT 2602260 T PT2602260 T PT 2602260T
- Authority
- PT
- Portugal
- Prior art keywords
- inhibitory activity
- preparing compound
- hiv integrase
- integrase inhibitory
- hiv
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Heat Sensitive Colour Forming Recording (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010175899 | 2010-08-05 | ||
| JP2010277713 | 2010-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2602260T true PT2602260T (en) | 2016-12-27 |
Family
ID=45559561
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT16190894T PT3127908T (en) | 2010-08-05 | 2011-08-04 | Process for preparing compound having hiv integrase inhibitory activity |
| PT118146901T PT2602260T (en) | 2010-08-05 | 2011-08-04 | Process for preparing compound having hiv integrase inhibitory activity |
| PT182035899T PT3456721T (en) | 2010-08-05 | 2011-08-04 | Method of producing compounds having hiv integrase inhivitory activity |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT16190894T PT3127908T (en) | 2010-08-05 | 2011-08-04 | Process for preparing compound having hiv integrase inhibitory activity |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT182035899T PT3456721T (en) | 2010-08-05 | 2011-08-04 | Method of producing compounds having hiv integrase inhivitory activity |
Country Status (18)
| Country | Link |
|---|---|
| US (8) | US20140011995A1 (en) |
| EP (3) | EP3456721B1 (en) |
| JP (1) | JP5636054B2 (en) |
| CN (3) | CN106046022B (en) |
| BR (1) | BR112013002461A2 (en) |
| CY (1) | CY1124582T1 (en) |
| DK (1) | DK3456721T3 (en) |
| ES (3) | ES2870006T3 (en) |
| HR (1) | HRP20210748T1 (en) |
| HU (1) | HUE054473T2 (en) |
| LT (1) | LT3456721T (en) |
| PL (1) | PL3456721T3 (en) |
| PT (3) | PT3127908T (en) |
| RS (1) | RS61796B1 (en) |
| SG (1) | SG187683A1 (en) |
| SI (1) | SI3456721T1 (en) |
| TW (1) | TWI510451B (en) |
| WO (1) | WO2012018065A1 (en) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5586602B2 (en) | 2008-07-25 | 2014-09-10 | ビーブ・ヘルスケア・カンパニー | Compound |
| AU2009325128B2 (en) | 2008-12-11 | 2015-01-29 | Shionogi & Co., Ltd. | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
| KR101682058B1 (en) | 2008-12-11 | 2016-12-02 | 비이브 헬쓰케어 컴퍼니 | Processes and intermediates for carbamoylpyridone hiv integrase inhibitors |
| TWI518084B (en) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | Process for pyrone and pyridone derivatives |
| TWI582097B (en) | 2010-03-23 | 2017-05-11 | Ｖｉｉｖ醫療保健公司 | Process for preparing carbamoylpyridone derivatives and intermediates |
| BR112013002461A2 (en) * | 2010-08-05 | 2016-05-24 | Shionogi & Co | method for producing a compound, and crystal of a compound |
| UY35213A (en) | 2012-12-21 | 2014-06-30 | Gilead Sciences Inc | COMPOUNDS OF THE TYPE OF POLYCYCLIC CARBAMYLPIRIDONS AND THEIR PHARMACEUTICAL USE |
| NO2865735T3 (en) | 2013-07-12 | 2018-07-21 | ||
| AU2014286993B2 (en) | 2013-07-12 | 2018-10-25 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their use for the treatment of HIV infections |
| IN2014CH00247A (en) | 2014-01-21 | 2015-08-14 | Laurus Labs Private Ltd | |
| CN106831819B (en) * | 2014-03-19 | 2019-01-04 | 杭州普晒医药科技有限公司 | The crystal form and preparation method thereof of De Luogewei sodium salt |
| NO2717902T3 (en) | 2014-06-20 | 2018-06-23 | ||
| TWI677489B (en) * | 2014-06-20 | 2019-11-21 | 美商基利科學股份有限公司 | Synthesis of polycyclic-carbamoylpyridone compounds |
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| EP3229804B1 (en) | 2014-12-09 | 2020-05-06 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors |
| WO2016092527A1 (en) * | 2014-12-12 | 2016-06-16 | Sun Pharmaceutical Industries Limited | A process for the preparation of dolutegravir |
| TWI738321B (en) | 2014-12-23 | 2021-09-01 | 美商基利科學股份有限公司 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| CN104557686A (en) * | 2014-12-29 | 2015-04-29 | 徐俊烨 | Synthesis method for pyridinone compound |
| EP3045461A1 (en) * | 2015-01-16 | 2016-07-20 | LEK Pharmaceuticals d.d. | Processes for preparing dolutegravir and analogues thereof |
| NZ735575A (en) | 2015-04-02 | 2018-11-30 | Gilead Sciences Inc | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| ES2742249T3 (en) * | 2015-12-21 | 2020-02-13 | Lupin Ltd | Process for the preparation of HIV integrase inhibitors |
| WO2017223280A2 (en) * | 2016-06-23 | 2017-12-28 | Viiv Healthcare Company | Compositions and methods for the delivery of therapeutics |
| JOP20190130A1 (en) | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors |
| WO2018229798A1 (en) * | 2017-06-13 | 2018-12-20 | Cipla Limited | Process for the preparation of bictegravir and intermediate thereof |
| SG11202002789XA (en) * | 2017-10-06 | 2020-04-29 | Shionogi & Co | Stereoselective process for preparing substituted polycyclic pyridone derivatives |
| CN108101838B (en) * | 2017-12-18 | 2020-10-20 | 安徽唯诗杨信息科技有限公司 | Synthesis method of dolutegravir intermediate and related substance detection method thereof |
| EP3820875B1 (en) | 2018-07-12 | 2024-01-17 | Laurus Labs Limited | A process for purification of protected polycyclic carbamoylpyridone derivatives |
| SG11202104117WA (en) | 2018-10-22 | 2021-05-28 | Univ Nebraska | Antiviral prodrugs and nanoformulations thereof |
| KR20210142711A (en) | 2019-03-22 | 2021-11-25 | 길리애드 사이언시즈, 인코포레이티드 | Cross-linked tricyclic carbamoylpyridone compounds and pharmaceutical uses thereof |
| CN110128448A (en) * | 2019-05-22 | 2019-08-16 | 博诺康源(北京)药业科技有限公司 | The synthetic method of diastereoisomer impurity in a kind of Du Lutewei raw material and intermediate |
| CN110396099A (en) * | 2019-05-22 | 2019-11-01 | 博诺康源(北京)药业科技有限公司 | The synthetic method of diastereoisomer impurity in a kind of Du Lutewei raw material |
| US20200398978A1 (en) | 2019-06-20 | 2020-12-24 | Bell Helicopter Textron Inc. | Low-drag rotor blade extension |
| US11248005B2 (en) | 2019-07-08 | 2022-02-15 | Lupin Limited | Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor |
| CN110698473B (en) * | 2019-10-08 | 2020-12-18 | 浙江大学 | Piperazinone-hydroxypyridone-5-carboxyl compound, preparation and application |
| JP7453399B2 (en) | 2020-02-24 | 2024-03-19 | ギリアード サイエンシーズ， インコーポレイテッド | Tetracyclic compounds and their use for treating HIV infection |
| CN111620891B (en) * | 2020-05-27 | 2023-07-14 | 上海启讯医药科技有限公司 | Polyteplavir key intermediate solvate polymorph and preparation method and application thereof |
| AR124071A1 (en) | 2020-11-17 | 2023-02-08 | Shionogi & Co | NEW ACRIDINIUM SALT AND METHOD OF PRODUCING IT |
| CN112480007B (en) * | 2020-12-08 | 2022-11-18 | 宿迁市科莱博生物化学有限公司 | Synthetic method of 1,3-dimethyl-1H-pyrazole-4-carboxylic acid |
| US11613546B2 (en) | 2021-01-19 | 2023-03-28 | Gilead Sciences, Inc. | Substituted pyridotriazine compounds and uses thereof |
| CN115572257B (en) * | 2021-06-21 | 2024-07-09 | 江西帝劢药业有限公司 | Synthesis method of pyridone compound |
| WO2023175386A2 (en) * | 2021-10-08 | 2023-09-21 | Laurus Labs Limited | Processes for preparation of cabotegravir or its pharmaceutically acceptable salts thereof |
| TWI843506B (en) | 2022-04-06 | 2024-05-21 | 美商基利科學股份有限公司 | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4769380A (en) | 1983-04-29 | 1988-09-06 | Merrell Dow Pharmaceuticals Inc. | Cardiotonic 5-benzoyl-1,2-dihydro-2-oxo-3-pyridinecarboxylates |
| JP4436229B2 (en) | 2004-10-20 | 2010-03-24 | 株式会社沖データ | Electronic equipment |
| US7858788B2 (en) | 2005-02-21 | 2010-12-28 | Shionogi & Co., Ltd. | Bicyclic carbamoylpyridone derivative having HIV integrase inhibitory activity |
| EP2465580B1 (en) | 2005-04-28 | 2013-12-18 | VIIV Healthcare Company | Polycyclic carbamoylpyridone derivatives having hiv integrase inhibitory activity |
| CN101212903B (en) * | 2005-04-28 | 2013-07-24 | 史密丝克莱恩比彻姆公司 | Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity |
| JP5297105B2 (en) | 2008-07-04 | 2013-09-25 | 株式会社クボタ | Ride type rice transplanter |
| JP4975690B2 (en) | 2008-07-07 | 2012-07-11 | アルファフーズ株式会社 | Method for producing retort food |
| ES2448766T3 (en) | 2008-07-25 | 2014-03-17 | Viiv Healthcare Company | Dolutegravir prodrugs |
| WO2010011819A1 (en) * | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| JP2010068253A (en) | 2008-09-10 | 2010-03-25 | Sony Corp | Encryption processing device |
| JP2010068262A (en) | 2008-09-11 | 2010-03-25 | New Japan Radio Co Ltd | Electronic volume |
| JP2010067176A (en) | 2008-09-12 | 2010-03-25 | Nec Corp | Information processor |
| AU2009325128B2 (en) * | 2008-12-11 | 2015-01-29 | Shionogi & Co., Ltd. | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
| JP5629268B2 (en) | 2008-12-11 | 2014-11-19 | 塩野義製薬株式会社 | Process for producing maltol ether and intermediate |
| KR101682058B1 (en) | 2008-12-11 | 2016-12-02 | 비이브 헬쓰케어 컴퍼니 | Processes and intermediates for carbamoylpyridone hiv integrase inhibitors |
| TWI518084B (en) * | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | Process for pyrone and pyridone derivatives |
| TWI582097B (en) * | 2010-03-23 | 2017-05-11 | Ｖｉｉｖ醫療保健公司 | Process for preparing carbamoylpyridone derivatives and intermediates |
| BR112013002461A2 (en) * | 2010-08-05 | 2016-05-24 | Shionogi & Co | method for producing a compound, and crystal of a compound |
-
2011
- 2011-08-04 BR BR112013002461A patent/BR112013002461A2/en not_active Application Discontinuation
- 2011-08-04 ES ES18203589T patent/ES2870006T3/en active Active
- 2011-08-04 US US13/814,333 patent/US20140011995A1/en not_active Abandoned
- 2011-08-04 ES ES16190894T patent/ES2710609T3/en active Active
- 2011-08-04 HU HUE18203589A patent/HUE054473T2/en unknown
- 2011-08-04 DK DK18203589.9T patent/DK3456721T3/en active
- 2011-08-04 CN CN201610447110.1A patent/CN106046022B/en active Active
- 2011-08-04 CN CN201610447148.9A patent/CN106083891B/en active Active
- 2011-08-04 CN CN201180048343.XA patent/CN103154004B/en active Active
- 2011-08-04 PT PT16190894T patent/PT3127908T/en unknown
- 2011-08-04 PL PL18203589T patent/PL3456721T3/en unknown
- 2011-08-04 EP EP18203589.9A patent/EP3456721B1/en active Active
- 2011-08-04 PT PT118146901T patent/PT2602260T/en unknown
- 2011-08-04 EP EP16190894.2A patent/EP3127908B1/en active Active
- 2011-08-04 EP EP11814690.1A patent/EP2602260B1/en active Active
- 2011-08-04 RS RS20210566A patent/RS61796B1/en unknown
- 2011-08-04 ES ES11814690.1T patent/ES2608377T3/en active Active
- 2011-08-04 SG SG2013008057A patent/SG187683A1/en unknown
- 2011-08-04 WO PCT/JP2011/067832 patent/WO2012018065A1/en active Application Filing
- 2011-08-04 LT LTEP18203589.9T patent/LT3456721T/en unknown
- 2011-08-04 SI SI201131966T patent/SI3456721T1/en unknown
- 2011-08-04 PT PT182035899T patent/PT3456721T/en unknown
- 2011-08-04 JP JP2012527760A patent/JP5636054B2/en active Active
- 2011-08-05 TW TW100127858A patent/TWI510451B/en active
-
2014
- 2014-10-20 US US14/518,209 patent/US9321789B2/en active Active
-
2016
- 2016-03-17 US US15/072,388 patent/US9650394B2/en active Active
-
2017
- 2017-03-28 US US15/471,133 patent/US9802959B2/en active Active
- 2017-09-20 US US15/709,701 patent/US10000508B2/en active Active
- 2017-09-20 US US15/709,742 patent/US9969750B2/en active Active
- 2017-09-20 US US15/709,716 patent/US10125146B2/en active Active
- 2017-09-20 US US15/709,728 patent/US10125147B2/en active Active
-
2021
- 2021-05-12 HR HRP20210748TT patent/HRP20210748T1/en unknown
- 2021-05-17 CY CY20211100423T patent/CY1124582T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2602260T (en) | Process for preparing compound having hiv integrase inhibitory activity | |
| HK1197400A1 (en) | Compounds for the treatment of hiv hiv | |
| EP2931730A4 (en) | 4-pyridinonetriazine derivatives as hiv integrase inhibitors | |
| EP2871957A4 (en) | Macrocyclic compounds as hiv integrase inhibitors | |
| EP2667714A4 (en) | Process for the preparation of 4-amino-5-fluoro-3-halo-6-(substituted)picolinates | |
| IL222266B (en) | Process for preparing solvent-free antiviral drug nano-dispersions | |
| SG10201505540SA (en) | Process for preparing antiviral compounds | |
| EP2635558A4 (en) | Process for preparing bendamus tine hydrochloride monohydrate | |
| EP2668163A4 (en) | Process for the preparation of 4-amino-3-chloro-5-fluoro-6-(substituted) picolinates | |
| ZA201305582B (en) | Process for the preparation of 4-amino-5-fluoro-3-halo-6-(sunstituted)picolinates | |
| EP2534127A4 (en) | Process for preparing (r)-2-acetamido-n-benzyl-3-methoxy-propionamide | |
| EP2877469A4 (en) | Substituted naphthyridinedione derivatives as hiv integrase inhibitors | |
| ZA201207386B (en) | Process for preparing benzoxaboroles | |
| HK1187493A1 (en) | Process for the preparation of 4-amino-3-chloro-5-fluoro-6- (substituted)picolinates 4--3--5--6-()-2- | |
| EP2391212A4 (en) | Bridged compounds as hiv integrase inhibitors | |
| IL230904A0 (en) | Process for the preparation of complexes of68ga | |
| EP2571811A4 (en) | Process for making titanium compounds | |
| EP2585436A4 (en) | Process for preparing 4-hydroxypyridines | |
| IL223145A0 (en) | Process for preparing dithiine-tetracarboxy-diimides | |
| EP2526091A4 (en) | Derivatives of pyridoxine for inhibiting hiv integrase | |
| EP2776388A4 (en) | A novel process for the preparation of (r)-n-benzyl-2 acetamido-3-methoxypropionamide | |
| EP2604591A4 (en) | Process for preparing aminoadamantyl carbamate derivatives | |
| EP2754655A4 (en) | Novel compound having angiogenesis inhibitory activity, method for preparing same, and pharmaceutical composition comprising same | |
| HK1201062A1 (en) | Process for the preparation of a statin precursor | |
| HK1201063A1 (en) | Process for the preparation of a thioprecursor for statins |